This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaPoint: Rheumatoid Arthritis - India Drug Forecast And Market Analysis Event-Driven Update

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of rheumatoid arthritis drug performance in India

- Obtain sales forecast from 2011-2022 in India

Table of Contents

1 Table of Contents 4



1.1 List of Tables 6



1.2 List of Figures 6



2 Introduction 7



2.1 Catalyst 7



2.2 Related Reports 8



3 Disease Overview 10



3.1 Etiology and Pathophysiology 10



3.1.1 Etiology 10



3.1.2 Pathophysiology 10



3.1.3 Prognosis 13



3.1.4 Quality of Life 13



3.2 Symptoms 14



4 Disease Management 15



4.1 Treatment Overview 18



4.2 India 22



4.2.1 Diagnosis 22



4.2.2 Clinical Practice 22



5 Competitive Assessment 24



5.1 Overview 24



5.2 Strategic Competitor Assessment 24



5.3 Product Profiles - Major Brands 26



5.3.1 Enbrel (etanercept) 26



5.3.2 Remicade (infliximab) 32



5.3.3 Orencia (abatacept) 36



5.3.4 Actemra/RoActemra (tocilizumab) 40



5.3.5 Rituxan/MabThera (rituximab) 44



5.3.6 Methotrexate Sodium (numerous generic names) 48



5.3.7 DMARDs 51



6 Opportunity and Unmet Need 52



6.1 Overview 52



6.2 Unmet Needs 53



6.2.1 More rheumatologists in the field and physician knowledge of the disease 53



6.2.2 More cost-effective therapies through oral formulation and biosimilars 53



6.2.3 The development of predictive tests and discovery of biomarkers 54



6.2.4 The discovery of curative therapies 54



6.2.5 Improved drug safety and efficacy profiles 54



6.3 Gap Analysis 55



6.4 Opportunities 56



6.4.1 Predictive tools for diagnosis and treatment 56



6.4.2 Target specificity 56



7 Pipeline Assessment 57



7.1 Overview 57



7.2 Promising Drugs in Clinical Development 58



8 Market Outlook 60



8.1 India 60



8.1.1 Forecast 60



8.1.2 Key Events 62



8.1.3 Drivers and Barriers 63



9 Appendix 65



9.1 Abbreviations 65

2 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs